Verona Pharma logo

Verona PharmaNASDAQ: VRNA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

28 April 2017

Next earnings report:

04 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.75 B
-3%vs. 3y high
84%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 6 min ago
$33.90-$0.60(-1.74%)

Dividend

No data over the past 3 years
$5.78 M$2.01 M

Analysts recommendations

Institutional Ownership

VRNA Latest News

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
globenewswire.com21 October 2024 Sentiment: POSITIVE

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
globenewswire.com30 September 2024 Sentiment: POSITIVE

Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
seekingalpha.com14 September 2024 Sentiment: POSITIVE

Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
globenewswire.com05 September 2024 Sentiment: POSITIVE

Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
seekingalpha.com08 August 2024 Sentiment: NEUTRAL

Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call.

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com08 August 2024 Sentiment: POSITIVE

Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.

Verona Pharma to Present at 44th Annual Canaccord Growth Conference
globenewswire.com30 July 2024 Sentiment: POSITIVE

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
globenewswire.com25 July 2024 Sentiment: POSITIVE

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
reuters.com27 June 2024 Sentiment: NEGATIVE

Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.

US FDA approves Verona Pharma's therapy for 'smoker's lungs'
reuters.com26 June 2024 Sentiment: POSITIVE

The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.

  • 1(current)
  • 2

What type of business is Verona Pharma?

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

What sector is Verona Pharma in?

Verona Pharma is in the Healthcare sector

What industry is Verona Pharma in?

Verona Pharma is in the Biotechnology industry

What country is Verona Pharma from?

Verona Pharma is headquartered in United Kingdom

When did Verona Pharma go public?

Verona Pharma initial public offering (IPO) was on 28 April 2017

What is Verona Pharma website?

https://www.veronapharma.com

Is Verona Pharma in the S&P 500?

No, Verona Pharma is not included in the S&P 500 index

Is Verona Pharma in the NASDAQ 100?

No, Verona Pharma is not included in the NASDAQ 100 index

Is Verona Pharma in the Dow Jones?

No, Verona Pharma is not included in the Dow Jones index

When was Verona Pharma the previous earnings report?

No data

When does Verona Pharma earnings report?

The next expected earnings date for Verona Pharma is 04 November 2024